Kezdőlap・Részvénylista・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Nyitva

3.5 -1.96

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.45

Maximum

3.65

Fő mutatók
By Trading Economics
Bevétel	-42M -78M
Egy részvényre jutó nyereség	-0.59
Munkavállalók	106
EBITDA	-42M -77M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+146.05% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 6.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	47M 378M
Előző nyitás	5.46
Előző zárás	3.5

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 10. 23:56 UTC

Correlated Moves

NiSource Inc shares are lower in after-market trading, continuing a decline from Thursday's close, alongside CMS Energy Corp's decrease amid broader market pressures.

2026. szept. 10. 23:56 UTC

Macro News

Copper prices are lower as rising crude oil prices above $100 create negative market sentiment. Increased treasury yields also contribute to cautious outlooks for commodities.

2026. szept. 10. 23:56 UTC

Plexus Corp shares rose in after-hours trading, rebounding sharply from an early decline. No specific news was identified to explain the movement.

2026. szept. 10. 23:56 UTC

State Street Corp shares are trading lower in after-market hours. No specific news was identified to explain this movement.

2026. szept. 10. 23:56 UTC

PPL Corp shares are trading slightly higher in after-market hours, reflecting a modest advance since Thursday's close amid recent trading pressure.

2026. szept. 10. 23:56 UTC

Dollar Tree Inc. shares are higher in after-market trading, gaining slightly since Thursday's close, though remaining below the 20-day moving average.

2026. szept. 10. 23:56 UTC

Flowers Foods Inc shares are higher in after-market trading, rebounding from an early dip. The stock remains below its 20-day moving average.

2026. szept. 10. 23:56 UTC

UFP Technologies Inc shares are higher in after-market trading, showing notable upward movement since Thursday's close, despite recent declines and no specific news.

2026. szept. 10. 23:56 UTC

Medtronic PLC shares are lower in after-market hours, continuing a trend from recent sessions. Volatility marked today's trading, with no specific news identified.

2026. szept. 10. 23:52 UTC

The AUD/CHF is trading lower today, with no specific news identified. It remains near the upper end of its one-month trading range.

2026. szept. 10. 23:51 UTC

News

The Nikkei 225 Index is lower in after-market hours, pressured by rising oil prices above $100 and a recent European Central Bank rate hike.

2026. szept. 10. 23:51 UTC

Shares of Frontier Group Holdings Inc. are lower in after-market hours, continuing a decline over the past four sessions amid broader market trends.

2026. szept. 10. 23:51 UTC

CVS Health shares are higher in after-market trading, rebounding from earlier losses amid mixed economic data and broader market trends.

2026. szept. 10. 23:51 UTC

Texas Pacific Land Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions finishing down and trading below the 20-day moving average.

2026. szept. 10. 23:51 UTC

iQIYI Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains below its 20-day moving average.

2026. szept. 10. 23:51 UTC

UiPath Inc. shares are lower in after-market trading, remaining below the 20-day moving average and near the lower end of their one-month range.

2026. szept. 10. 23:51 UTC

Progressive Corp shares are lower in after-market hours. No specific news was identified to explain the decline.

2026. szept. 10. 23:51 UTC

Regal Rexnord Corp shares rose in after-market trading, recovering from an initial dip. The price remains below its 20-day moving average.

2026. szept. 10. 23:51 UTC

Michigan Consumer Sentiment Preliminary Report for September 2026 Forecasts Continued Low Confidence at 51.0 Amid Rising Inflation Concerns

2026. szept. 10. 23:51 UTC

Canada's Housing Starts Data Release on September 16, 2026, Sparks Concerns Over Slowing Construction and Affordability Challenges.

2026. szept. 10. 23:51 UTC

Macro News

The Euro Stoxx 50 Index is lower in after-market hours, pressured by rising crude oil prices above $100 and concerns over inflation and interest rates.

2026. szept. 10. 23:51 UTC

Consolidated Edison shares moved higher in after-hours trading, recovering from a session low. The stock is positioned near the midpoint of its one-month trading range.

2026. szept. 10. 23:51 UTC

Zeta Global Holdings Corp. shares are lower in after-market hours, continuing a downward trend observed since Thursday's close amid broader market conditions.

2026. szept. 10. 23:51 UTC

Correlated Moves

WEC Energy Group shares are higher in after-market hours, influenced by a rise in Consolidated Edison and broader utility sector trends.

2026. szept. 10. 23:51 UTC

APTIV PLC shares are lower in after-market hours, continuing a downward trend since Thursday's close. The stock remains below its 20-day moving average.

2026. szept. 10. 23:51 UTC

The AUD/JPY is trading lower, continuing a downward trend since Wednesday. It remains near the lower end of its one-month trading range.

2026. szept. 10. 23:51 UTC

The AUD/NZD is trading lower today, with no specific news identified for the decline. It remains below Wednesday's close after earlier fluctuations.

2026. szept. 10. 23:46 UTC

Correlated Moves

Parker-Hannifin Corp shares are lower in after-market hours, continuing recent declines influenced by Timken Co's drop and broader industrial sector sentiment.

2026. szept. 10. 23:46 UTC

Correlated Moves

News

Valero Energy Corp is trading higher in after-market hours following a Power Inflow alert, reflecting increased buying interest among investors.

2026. szept. 10. 23:46 UTC

Leidos Holdings Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

146.05% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.833 USD 146.05%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

Vétel

Tartás

Eladás

6 Wall Street elemző célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.